Merck & Co Stock Price, News & Analysis

Merck (NYSE: MRK) announced that its KEYTRUDA therapy combined with chemotherapy has met the primary endpoint of overall survival (OS) in the Phase 2/3 IND.227/KEYNOTE-483 trial for patients with unresectable advanced or metastatic malignant pleural mesothelioma. This collaboration with the Canadian Cancer Trials Group, and co-sponsored by entities in Italy and France, demonstrated a statistically significant improvement in OS for the combination treatment compared to chemotherapy alone. The safety profile of KEYTRUDA remains consistent with previous studies. Results will be presented at a future medical meeting.

Merck (NYSE: MRK) announced that Jannie Oosthuizen, President of Human Health U.S., will participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on March 15, 2023, at 2:35 p.m. ET. The event is open for investors, analysts, and the general public to listen via a live audio webcast. Merck emphasizes its commitment to utilizing leading-edge science to enhance lives globally. The company has over 130 years of experience in developing significant medicines and vaccines, aiming to lead in innovative health solutions for disease prevention and treatment.

Merck & Co., Inc. recently highlighted its rich history of diversity and innovation, focusing on the contributions of Black leaders within the company. Key figures include:

• Susan R. Jenkins, one of the first female Black chemists at Merck, noted for her role in synthesizing ribonuclease and her advocacy for equal employment.
• William Bowers, a prominent civil rights advocate, co-founded the Black Employees Network at Merck.
• Jimmy Dean, a former Negro League baseball star, transitioned into a successful career at Merck.

This commitment to diversity is also reflected in various programs aimed at enhancing opportunities for Black and minority employees.

Merck (NYSE: MRK) announced promising results from its Phase 3 STELLAR trial for sotatercept, an investigational biologic for treating pulmonary arterial hypertension (PAH). The study showed a significant improvement in exercise capacity with a 40.8 meters increase in six-minute walk distance (p<0.001) from baseline at week 24. Notably, sotatercept reduced the risk of clinical worsening or death by 84%. Eight out of nine secondary measures also showed significant improvements. The results were shared at the ACC.23/WCC and published in The New England Journal of Medicine. Merck plans to discuss these impactful findings with health authorities.

Merck (NYSE: MRK) announced positive results from its Phase 2b clinical trial for MK-0616, a novel oral PCSK9 inhibitor aimed at lowering LDL cholesterol in adults with hypercholesterolemia. The trial demonstrated significant reductions in LDL-C levels, ranging from 41.2% to 60.9% across various doses at 8 weeks compared to placebo. MK-0616 was well-tolerated, with no serious adverse events reported. Merck plans to initiate a Phase 3 pivotal study in the second half of 2023, potentially positioning MK-0616 as the first oral treatment of its kind, improving accessibility for patients at risk of cardiovascular disease.

Merck (NYSE: MRK) has received FDA approval for the intramuscular (IM) administration of its MMRV family of vaccines: M-M-R® II, VARIVAX®, and ProQuad®. This expansion allows healthcare professionals to administer these vaccines alongside other recommended pediatric vaccinations, enhancing vaccination options. Previously, these vaccines were only available via subcutaneous (SC) injection. The MMRV vaccines are crucial in preventing measles, mumps, rubella, and varicella, with historical approvals dating back to 1978 for M-M-R® II. The IM route is already licensed in the EU, marking a significant advancement in vaccination practices for children in the U.S.

AstraZeneca and Merck (NYSE: MRK) announced that the FDA will convene the Oncologic Drugs Advisory Committee (ODAC) on April 28, 2023, to discuss the supplemental new drug application (sNDA) for LYNPARZA, used in combination with abiraterone and prednisone for treating metastatic castration-resistant prostate cancer (mCRPC). The sNDA is based on results from the Phase 3 PROpel trial, showing improved radiographic progression-free survival. LYNPARZA is already approved in the EU for this combination. The meeting provides expert guidance but is advisory only, as the FDA makes the final decision.

Merck (NYSE: MRK) announced positive results from the Phase 3 KEYNOTE-671 trial, showing KEYTRUDA® (pembrolizumab) combined with chemotherapy significantly improved event-free survival (EFS) in patients with resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC). The trial also reported statistically significant enhancements in secondary endpoints, including pathological complete response (pCR) and major pathological response (mPR). The FDA has accepted Merck's supplemental Biologics License Application (sBLA), with a PDUFA date set for October 16, 2023. No new safety signals were noted, and results will be shared at an upcoming medical meeting.

Merck (NYSE: MRK) announced the discontinuation of the Phase 3 KEYNOTE-641 trial for KEYTRUDA® (pembrolizumab) in combination with enzalutamide and androgen deprivation therapy for metastatic castration-resistant prostate cancer (mCRPC). The decision follows an independent committee's recommendation due to lack of improvement in radiographic progression-free survival (rPFS) and overall survival (OS). Additionally, the KEYNOTE-789 trial for KEYTRUDA with pemetrexed and platinum-based chemotherapy also failed to meet its OS primary endpoint for patients with metastatic nonsquamous non-small cell lung cancer. Safety profiles remained consistent with earlier studies.